Tarlatamab-dlle

{
  "id": "MLC-T-ONC-016986",
  "term": "Tarlatamab-dlle",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) fused to one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, tarlatamab binds to both the CD3 antigen on cytotoxic T lymphocytes (CTLs) and the DLL3 antigen found on DLL3-expressing tumor cells. This activates and redirects CTLs to DLL3-expressing tumor cells, which results in the CTL-mediated cell death of DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.",
  "synonyms": [
    "tarlatamab",
    "bispecific T-cell engager antibody AMG 757",
    "BiTE antibody AMG 757",
    "DLL3/CD3-directed bispecific T-cell engager antibody AMG 757",
    "anti-DLL3 x anti-CD3 BiTE AMG 757"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tarlatamab-dlle/"
}